Heterogeneous epigenetic regulation of TIMP3 in prostate cancer

Toshiaki Shinojima, Qiang Yu, Sharon K. Huang, Michelle Li, Ryuichi Mizuno, Edison T. Liu, Dave S B Hoon, Laurent Lessard

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Tissue inhibitor of metalloproteinase-3 (TIMP3) is a tumor suppressor gene frequently downregulated in prostate cancer. The mechanisms involved in TIMP3 transcriptional repression are not fully understood, but evidence suggests that promoter hypermethylation may not be the predominant epigenetic alteration in prostate cancer. To clarify this issue, we examined the contribution of both CpG site promoter methylation and histone modifications on TIMP3 downregulation. Using publicly available data sets, we confirmed that TIMP3 mRNA expression is decreased in prostate tumors relative to normal glands. Immunohistochemical analysis also showed decreased TIMP3 levels in high-grade primary tumors, but promoter hypermethylation was only detected in 6 of 28 (21%) high-grade specimens. Similarly, in prostate cancer cells, TIMP3 hypermethylation was only observed in DU145 cells. Treatment of DU145 cells with 5-aza-2'-deoxycytidine (5-Aza-CdR) restored TIMP3 expression, and this was significantly amplified by co-treating the cells with the HDAC inhibitor trichostatin A (TSA). Alternatively, in cells that did not exhibit aberrant TIMP3 methylation (LNCaP and PC 3), TIMP3 expression could be upregulated by the combination of histone methylation inhibitor 3-Deazaneplanocin A (DZNep) and TSA. This reversal of transcriptional repression was associated with decreased H3K27me3 and increased H3K9ac histone marks at the TIMP3 promoter, as demonstrated by chromatin immunoprecipitation. Collectively, these results indicate that histone modifications can contribute to TIMP3 repression in the absence of promoter hypermethylation, and suggest that the combination of histone modifying agents could restore TIMP3 expression in prostate tumors harboring aberrant histone modifications at the TIMP3 promoter.

Original languageEnglish
Pages (from-to)1279-1289
Number of pages11
JournalEpigenetics
Volume7
Issue number11
DOIs
Publication statusPublished - 2012 Nov
Externally publishedYes

Fingerprint

Tissue Inhibitor of Metalloproteinase-3
Epigenomics
Prostatic Neoplasms
Histone Code
trichostatin A
Methylation
decitabine
Histones
Prostate
Down-Regulation
Choristoma
Histone Deacetylase Inhibitors
Chromatin Immunoprecipitation
Tumor Suppressor Genes
Carcinogens

Keywords

  • DNA methylation
  • Epigenetic drugs
  • Histone modifications
  • Prostate cancer
  • TIMP3

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research

Cite this

Shinojima, T., Yu, Q., Huang, S. K., Li, M., Mizuno, R., Liu, E. T., ... Lessard, L. (2012). Heterogeneous epigenetic regulation of TIMP3 in prostate cancer. Epigenetics, 7(11), 1279-1289. https://doi.org/10.4161/epi.22333

Heterogeneous epigenetic regulation of TIMP3 in prostate cancer. / Shinojima, Toshiaki; Yu, Qiang; Huang, Sharon K.; Li, Michelle; Mizuno, Ryuichi; Liu, Edison T.; Hoon, Dave S B; Lessard, Laurent.

In: Epigenetics, Vol. 7, No. 11, 11.2012, p. 1279-1289.

Research output: Contribution to journalArticle

Shinojima, T, Yu, Q, Huang, SK, Li, M, Mizuno, R, Liu, ET, Hoon, DSB & Lessard, L 2012, 'Heterogeneous epigenetic regulation of TIMP3 in prostate cancer', Epigenetics, vol. 7, no. 11, pp. 1279-1289. https://doi.org/10.4161/epi.22333
Shinojima T, Yu Q, Huang SK, Li M, Mizuno R, Liu ET et al. Heterogeneous epigenetic regulation of TIMP3 in prostate cancer. Epigenetics. 2012 Nov;7(11):1279-1289. https://doi.org/10.4161/epi.22333
Shinojima, Toshiaki ; Yu, Qiang ; Huang, Sharon K. ; Li, Michelle ; Mizuno, Ryuichi ; Liu, Edison T. ; Hoon, Dave S B ; Lessard, Laurent. / Heterogeneous epigenetic regulation of TIMP3 in prostate cancer. In: Epigenetics. 2012 ; Vol. 7, No. 11. pp. 1279-1289.
@article{6103f75cfc7448359d70bcb5742c7807,
title = "Heterogeneous epigenetic regulation of TIMP3 in prostate cancer",
abstract = "Tissue inhibitor of metalloproteinase-3 (TIMP3) is a tumor suppressor gene frequently downregulated in prostate cancer. The mechanisms involved in TIMP3 transcriptional repression are not fully understood, but evidence suggests that promoter hypermethylation may not be the predominant epigenetic alteration in prostate cancer. To clarify this issue, we examined the contribution of both CpG site promoter methylation and histone modifications on TIMP3 downregulation. Using publicly available data sets, we confirmed that TIMP3 mRNA expression is decreased in prostate tumors relative to normal glands. Immunohistochemical analysis also showed decreased TIMP3 levels in high-grade primary tumors, but promoter hypermethylation was only detected in 6 of 28 (21{\%}) high-grade specimens. Similarly, in prostate cancer cells, TIMP3 hypermethylation was only observed in DU145 cells. Treatment of DU145 cells with 5-aza-2'-deoxycytidine (5-Aza-CdR) restored TIMP3 expression, and this was significantly amplified by co-treating the cells with the HDAC inhibitor trichostatin A (TSA). Alternatively, in cells that did not exhibit aberrant TIMP3 methylation (LNCaP and PC 3), TIMP3 expression could be upregulated by the combination of histone methylation inhibitor 3-Deazaneplanocin A (DZNep) and TSA. This reversal of transcriptional repression was associated with decreased H3K27me3 and increased H3K9ac histone marks at the TIMP3 promoter, as demonstrated by chromatin immunoprecipitation. Collectively, these results indicate that histone modifications can contribute to TIMP3 repression in the absence of promoter hypermethylation, and suggest that the combination of histone modifying agents could restore TIMP3 expression in prostate tumors harboring aberrant histone modifications at the TIMP3 promoter.",
keywords = "DNA methylation, Epigenetic drugs, Histone modifications, Prostate cancer, TIMP3",
author = "Toshiaki Shinojima and Qiang Yu and Huang, {Sharon K.} and Michelle Li and Ryuichi Mizuno and Liu, {Edison T.} and Hoon, {Dave S B} and Laurent Lessard",
year = "2012",
month = "11",
doi = "10.4161/epi.22333",
language = "English",
volume = "7",
pages = "1279--1289",
journal = "Epigenetics",
issn = "1559-2294",
publisher = "Landes Bioscience",
number = "11",

}

TY - JOUR

T1 - Heterogeneous epigenetic regulation of TIMP3 in prostate cancer

AU - Shinojima, Toshiaki

AU - Yu, Qiang

AU - Huang, Sharon K.

AU - Li, Michelle

AU - Mizuno, Ryuichi

AU - Liu, Edison T.

AU - Hoon, Dave S B

AU - Lessard, Laurent

PY - 2012/11

Y1 - 2012/11

N2 - Tissue inhibitor of metalloproteinase-3 (TIMP3) is a tumor suppressor gene frequently downregulated in prostate cancer. The mechanisms involved in TIMP3 transcriptional repression are not fully understood, but evidence suggests that promoter hypermethylation may not be the predominant epigenetic alteration in prostate cancer. To clarify this issue, we examined the contribution of both CpG site promoter methylation and histone modifications on TIMP3 downregulation. Using publicly available data sets, we confirmed that TIMP3 mRNA expression is decreased in prostate tumors relative to normal glands. Immunohistochemical analysis also showed decreased TIMP3 levels in high-grade primary tumors, but promoter hypermethylation was only detected in 6 of 28 (21%) high-grade specimens. Similarly, in prostate cancer cells, TIMP3 hypermethylation was only observed in DU145 cells. Treatment of DU145 cells with 5-aza-2'-deoxycytidine (5-Aza-CdR) restored TIMP3 expression, and this was significantly amplified by co-treating the cells with the HDAC inhibitor trichostatin A (TSA). Alternatively, in cells that did not exhibit aberrant TIMP3 methylation (LNCaP and PC 3), TIMP3 expression could be upregulated by the combination of histone methylation inhibitor 3-Deazaneplanocin A (DZNep) and TSA. This reversal of transcriptional repression was associated with decreased H3K27me3 and increased H3K9ac histone marks at the TIMP3 promoter, as demonstrated by chromatin immunoprecipitation. Collectively, these results indicate that histone modifications can contribute to TIMP3 repression in the absence of promoter hypermethylation, and suggest that the combination of histone modifying agents could restore TIMP3 expression in prostate tumors harboring aberrant histone modifications at the TIMP3 promoter.

AB - Tissue inhibitor of metalloproteinase-3 (TIMP3) is a tumor suppressor gene frequently downregulated in prostate cancer. The mechanisms involved in TIMP3 transcriptional repression are not fully understood, but evidence suggests that promoter hypermethylation may not be the predominant epigenetic alteration in prostate cancer. To clarify this issue, we examined the contribution of both CpG site promoter methylation and histone modifications on TIMP3 downregulation. Using publicly available data sets, we confirmed that TIMP3 mRNA expression is decreased in prostate tumors relative to normal glands. Immunohistochemical analysis also showed decreased TIMP3 levels in high-grade primary tumors, but promoter hypermethylation was only detected in 6 of 28 (21%) high-grade specimens. Similarly, in prostate cancer cells, TIMP3 hypermethylation was only observed in DU145 cells. Treatment of DU145 cells with 5-aza-2'-deoxycytidine (5-Aza-CdR) restored TIMP3 expression, and this was significantly amplified by co-treating the cells with the HDAC inhibitor trichostatin A (TSA). Alternatively, in cells that did not exhibit aberrant TIMP3 methylation (LNCaP and PC 3), TIMP3 expression could be upregulated by the combination of histone methylation inhibitor 3-Deazaneplanocin A (DZNep) and TSA. This reversal of transcriptional repression was associated with decreased H3K27me3 and increased H3K9ac histone marks at the TIMP3 promoter, as demonstrated by chromatin immunoprecipitation. Collectively, these results indicate that histone modifications can contribute to TIMP3 repression in the absence of promoter hypermethylation, and suggest that the combination of histone modifying agents could restore TIMP3 expression in prostate tumors harboring aberrant histone modifications at the TIMP3 promoter.

KW - DNA methylation

KW - Epigenetic drugs

KW - Histone modifications

KW - Prostate cancer

KW - TIMP3

UR - http://www.scopus.com/inward/record.url?scp=84868348205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868348205&partnerID=8YFLogxK

U2 - 10.4161/epi.22333

DO - 10.4161/epi.22333

M3 - Article

C2 - 23023649

AN - SCOPUS:84868348205

VL - 7

SP - 1279

EP - 1289

JO - Epigenetics

JF - Epigenetics

SN - 1559-2294

IS - 11

ER -